YOLFTbeta
Vivoryon Therapeutics NV

Vivoryon Therapeutics NV

VVY · AS · Healthcare / Biotechnology

0.768EUR+0.01 (+1.32%)

Price History

Full chart

Market Stats

Previous Close0.758
Open0.766
Day Range0.744 – 0.768
52-Week Range1.00 – 1.84
Volume45.92K
Market Cap31.10M
P/E (TTM)0.00
Forward P/E42.19
EPS-0.23
Dividend Yield0.00%
Beta1.40
50-Day Avg1.13
200-Day Avg1.27

About

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Frank T. Weber M.D.
  • Employees13
  • HeadquartersWeinbergweg 22, Halle, Germany, 06120, Netherlands
  • Websitehttps://www.vivoryon.com

Leadership

  • Dr. Frank T. Weber M.D.MD, CEO, Chief Medical Officer & Executive Director · b. 1960
  • Mr. Marcus IrsfeldCFO & Executive Director · b. 1966
  • Dr. Julia Neugebauer Ph.D.Head of Investor Relations & Communications, COO & Executive Board Member · b. 1979
  • Dr. Michael Schaeffer Ph.D.Chief Business Officer & Executive Director · b. 1969
  • Dr. Manuela BaderDirector of Investor Relations & Communications
  • Dr. Konrad GlundCo-Founder & Advisor · b. 1953
  • Dr. Hendrik LiebersAdvisor · b. 1971

Financials

Income Statement

Currency: EUR2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue21.00K6.00K---0000010.76M0-3.62M00
Growth (%)--71.43%----------100.00%-+100.00%-
Cost of Revenue----56.00K97.00K106.00K23.00K88.00K146.00K1.73M161.00K-525.00K147.00K147.00K
Gross Profit21.00K6.00K---56.00K-97.00K-106.00K-23.00K-88.00K-146.00K9.03M-161.00K-3.10M-147.00K-147.00K
Gross Margin100.00%100.00%--------83.89%-85.50%--
Operating Expense14.29M10.56M--13.38M13.76M9.86M7.70M7.69M15.87M21.84M28.97M25.74M20.81M9.03M
Operating Income-14.27M-10.56M-9.65M-11.27M-13.44M-13.86M-9.96M-7.73M-7.77M-16.02M-12.81M-29.13M-28.84M-20.96M-9.18M
Operating Margin-67947.62%-175966.67%---------118.97%-796.60%--
EBITDA-13.78M-10.18M-9.34M-11.17M-13.34M-13.68M-9.86M-7.67M-7.63M-16.34M-12.03M-28.17M-28.35M-20.34M-9.03M
EBITDA Margin-65604.76%-169666.67%---------111.80%-783.23%--
Net Income-16.31M-18.72M-9.93M-11.44M-13.51M-13.89M-8.01M-7.74M-7.82M-16.51M-12.65M-28.16M-28.34M-20.57M-8.85M
Net Income Margin-77652.38%-312000.00%---------117.57%-782.93%--
R&D13.23M9.26M8.00M8.01M10.16M10.95M7.45M4.84M4.75M13.21M17.45M20.22M17.64M14.06M4.38M
R&D as % of Total Revenue62995.24%154250.00%--------162.13%--487.21%--
Interest Expense71.00K340.00K115.00K--0041.00K108.00K23.00K24.00K24.00K56.00K86.00K45.00K
Interest Expense % of Total Revenue338.10%5666.67%--------0.22%--1.55%--

Balance Sheet

Currency: EUR2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.97M19.09M10.01M6.37M21.48K21.87K22.37K10.76K4.05K45.86M29.75M24.52M31.38M30.83M11.28M7.52M
Total Liabilities3.73M4.15M4.64M10.60M5.51K5.73K5.99K1.84K2.82K3.20M3.53M7.96M4.87M4.55M3.40M2.79M
Total Equity12.24M14.95M5.37M-4.22M15.97K16.13K16.38K8.92K1.23K42.66M26.22M16.56M26.51M26.28M7.88M4.73M
Cash6.06M9.29M7.73M4.88M20.92K21.36K21.90K10.29K3.78K41.52M26.31M14.66M26.55M18.56M9.37M5.62M
Total Debt---5.35M-----406.00K314.00K224.00K132.00K38.00K102.00K108.00K
Net Debt-6.06M-9.29M-7.73M467.00K-20.92K-21.36K-21.90K-10.29K-3.78K-41.12M-25.99M-14.44M-26.42M-18.52M-9.26M-5.51M

Cash Flow

Currency: EUR2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.32M-12.04M-8.53M-10.59K-12.15K-13.26K-12.12K-6.99K-11.61M-14.01M-11.26M-21.79M-21.54M-19.17M-8.46M
Investing Cash Flow-1.09M1.27M333.00K1.33K-10-124459460-47.00K-640.00K-28.00K-13.00K-10.51M10.00M-6.00K
Financing Cash Flow18.64M9.20M5.35M25.76K12.60K13.91K12749.35M49.35M-90.00K-827.00K33.38M24.16M-57.00K4.71M
Capital Expenditure98.00K119.00K65.00K26771647.00K640.00K28.00K13.00K514.00K2.00K6.00K
Free Cash Flow-14.42M-12.16M-8.59M-10.59K-12.15K-13.26K-12.12K-7.01K-11.65M-14.65M-11.29M-21.81M-22.05M-19.18M-8.46M
FCF to OCF100.68%100.99%100.76%100.02%100.05%100.05%100.06%100.23%100.40%104.57%100.25%100.06%102.39%100.01%100.07%

Earnings

Report DateMar 30, 2017Aug 31, 2017Aug 30, 2018Mar 28, 2019Aug 29, 2019Mar 26, 2020Aug 27, 2020Sep 21, 2021Sep 30, 2022Mar 30, 2023Sep 7, 2023Jan 8, 2024Sep 12, 2024Sep 4, 2025Nov 3, 2026
EPS Estimate-1.100.000.00-0.39-0.35-0.26-0.39-0.58-0.06-0.61-0.60-0.52-0.63-0.79-
EPS Actual-1.01-0.53-0.50-0.43-0.310.30-0.38-0.58-0.600.000.000.00-0.52-0.21-
Surprise8.18%---10.26%11.43%215.38%2.56%0.00%-900.00%100.00%100.00%100.00%17.46%73.42%-
Timing--------After-hours-Pre-marketAfter-hours-After-hoursPre-market

Key Statistics & Ratios

Market Cap31.10M
Enterprise Value30.11M
Trailing P/E0.00
Forward P/E42.19
Price / Sales26.60
Price / Book20.82
EPS-0.23
Book Value0.053
Revenue (TTM)-3.62M
Gross Profit (TTM)-3.10M
EBITDA-6.70M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-285.21%
Return on Assets-80.06%
Shares Outstanding29.61M
Shares Float26.35M
Beta1.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%